Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: A pooled analysis of two 6-week, double-blind, placebo-controlled studies

International Clinical Psychopharmacology

Volumn 27, Issue 1, 2012, Pages 27-39

  Weisler, Richard H ^a,b   Montgomery, Stuart A ^c   Earley, Willie R ^d   Szamosi, Johan ^e   Lazarus, Arthur ^d  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d ASTRAZENECA   (United Kingdom)

^e ASTRAZENECA R AND D   (Sweden)

Author keywords

antidepressant; efficacy; extended release; major depressive disorder; quetiapine; randomized study

Indexed keywords

PLACEBO; QUETIAPINE;

ADULT; AGED; ARTICLE; BACKACHE; BODY WEIGHT; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; HAMILTON SCALE; HUMAN; INCREASED APPETITE; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; MYALGIA; NAUSEA; OUTPATIENT DEPARTMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCORING SYSTEM; SEDATION; SIDE EFFECT; SOMNOLENCE; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE ATTEMPT; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PLACEBOS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 83055186626     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32834d6f91     Document Type: Article

References (49)

1. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder, Third edition (2010), revised 2010. Available at http://www.psych.org/Departments/QIPS/Downloads/MDD-2010.aspx. [Accessed 21 July 2011].
2. AstraZeneca. Seroquel XR (quetiapine fumarate) extended release tablets/US Prescribing information, revised 2011a. Available at http://www1.astrazene-ca-us.com/pi/seroquelxr.pdf. [Accessed 25 August 2011].
3. AstraZeneca. Seroquel XR: Summary of Product Characteristics for Ireland, revised 2011b. Available at http://www.medicines.ie/medicine/13032/SPC/ Seroquel+XR+50mg%2c+150mg%2c+200mg%2c+300mg%2c+ 400mg + prolonged-release + tablets/. [Accessed 25 August 2011].
4. AstraZeneca. Seroquel XR product monograph (Canada), revised 2011c. Available at http://www.astrazeneca.ca/documents/ProductPortfolio/SERO- QUEL%20XR-PM-en.pdf. [Accessed 21 July 2011].
5. AstraZeneca Australia. Consumer Medicine Information, revised 2011. Available at http://www.astrazeneca.com.au/-mshost383378/content/legacy-site- con-tent/resources/media/396789/SeroquelXR-210211-cmi. [Accessed 21 July 2011].
6. Bauer M, Bschor T, Pfennig A, Whybrow PC, Angst J, Versiani M, et al. (2007). World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry 8:67-104. (Pubitemid 46690921)
7. Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, Brecher M (2009). Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: Results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 70:540-549.
8. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, et al. (2007). The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 68:843-853. (Pubitemid 47015482)
9. Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, et al. (2009). Aripiprazole augmentation in major depressive disorder: A double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 14:197-206.
10. Bolton JM, Pagura J, Enns MW, Grant B, Sareen J (2010). A population-based longitudinal study of risk factors for suicide attempts in major depressive disorder. J Psychiatr Res 44:817-826.
11. Bortnick B, El-Khalili N, Banov M, Adson D, Datto C, Raines S, et al. (2011). Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: A placebo-controlled, randomized study. J Affect Disord 128:83-94.
12. Calabrese JR, Keck PE Jr., Macfadden W, Minkwitz M, Ketter TA, Weisler RH, et al. (2005). A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 162:1351-1360. (Pubitemid 40905587)
13. Canuso CM, Turkoz I, Sheehan JJ, Bossie CA (2009). Efficacy and safety of paliperidone extended-release in schizophrenia patients with prominent affective symptoms. J Affect Disord 120:193-199.
14. Chellappa SL, Araujo JF (2007). Sleep disorders and suicidal ideation in patients with depressive disorder. Psychiatry Res 153:131-136. (Pubitemid 47539588)
15. Connolly KR, Thase ME (2011). If at first you don't succeed: A review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs 71:43-64.
16. Cutler A, Datto C, Nordenhem A, Minkwitz M, Dettore B, Acevedo L, Darko D. 2008 ). Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar mania. Poster presented at the 161st Annual Meeting of the American Psychiatric Association, Washington, DC, USA, 3-8 May.
17. Cutler AJ, Montgomery SA, Feifel D, Lazarus A, Aström M, Brecher M (2009). Extended release quetiapine fumarate monotherapy in major depressive disorder: A placebo-and duloxetine-controlled study. J Clin Psychiatry 70:526-539.
18. El-Khalili N, Joyce M, Atkinson S, Buynak R, Datto C, Lindgren P, et al. (2010). Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: A multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol 13: 917-932.
19. Fava M (2003). Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 53:649-659. (Pubitemid 39658481)
20. Fawcett J, Scheftner WA, Fogg L, Clark DC, Young MA, Hedeker D, et al. (1990). Time-related predictors of suicide in major affective disorder. Am J Psychiatry 147:1189-1194. (Pubitemid 20275373)
21. Hamilton M (1959). The assessment of anxiety states by rating. Br J Med Psychol 32:50-55.
22. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
23. Hansen RA, Gartlehner G, Lohr KN, Gaynes BN, Carey TS (2005). Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 143:415-426. (Pubitemid 41341413)
24. Howland RH (2008). Sequenced Treatment Alternatives to Relieve Depression (STAR*D). Part 2: Study outcomes. J Psychosoc Nurs Ment Health Serv 46:21-24.
25. Kahn RS, Schulz SC, Palazov VD, Reyes EB, Brecher M, Svensson O, et al. (2007). Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: A randomized, double-blind, placebo-controlled study. J Clin Psychiatry 68:832-842. (Pubitemid 47015481)
26. Keitner GI, Garlow SJ, Ryan CE, Ninan PT, Solomon DA, Nemeroff CB, et al. (2009). A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res 43:205-214.
27. Kennedy SH (2008). Core symptoms of major depressive disorder: Relevance to diagnosis and treatment. Dialogues Clin Neurosci 10:271-277.
28. Kessler RC, Merikangas KR, Wang PS (2007). Prevalence, comorbidity, and service utilization for mood disorders in the United States at the beginning of the twenty-first century. Annu Rev Clin Psychol 3:137-158. (Pubitemid 46651124)
29. Liebowitz M, Lam RW, Lepola U, Datto C, Sweitzer D, Eriksson H (2010). Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: A randomized, placebo-controlled trial. Depress Anxiety 27:964-976.
30. Mahmoud RA, Pandina GJ, Turkoz I, Kosik-Gonzalez C, Canuso CM, Kujawa MJ, et al. (2007). Risperidone for treatment-refractory major depressive disorder: A randomized trial. Ann Intern Med 147:593-602. (Pubitemid 351664478)
31. McElroy S, Weisler RH, Chang W, Olausson B, Paulsson B, Brecher M, et al. (2010). A double-blind, placebo-controlled study of quetiapine and paro-xetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 71:163-174.
32. McIntyre RS, Konarski JZ, Soczynska JK, Kennedy SH (2007). Residual anxiety symptoms in depressed primary care patients. J Psychiatr Pract 13:125-128. (Pubitemid 46588317)
33. Melander H, Salmonson T, Abadie E, Van Zwieten-Boot B (2008). A regulatory apologia: A review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. Eur Neuropsychopharmacol 18:623-627.
34. Mendlewicz J (2009). Sleep disturbances: Core symptoms of major depressive disorder rather than associated or comorbid disorders. World J Biol Psychiatry 10:269-275.
35. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389. (Pubitemid 9136500)
36. Montgomery SA, Moller HJ (2009). Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? Int Clin Psycho-pharmacol 24:111-118.
37. National Institute for Health and Clinical Excellence. Depression: The treatment and management of depression in adults (National Clinical Practice Guideline 90), revised, 2009. Available at: Http://www.nice.org.uk/nicemedia/ pdf/Depression-Update-FULL-GUIDELINE.pdf. [Accessed 21 July 2011]
38. Nyberg S, Widzowski D (2010). Translational pharmacology of quetiapine and norquetiapine: Preclinical findings support multifunctional psychotropic properties. Eur Psychiatry 25:1446.
39. Nyberg S, Takano A, Jucaite A, Karlsson P, McCarthy D, Kagedal M, et al. (2008). PET-measured occupancy of the NET by extended release quetiapine fumarate (quetiapine XR) in brains of healthy subjects. Eur Neuropsycho- pharmacol 18:S270.
40. Rush AJ (2007). Limitations in efficacy of antidepressant monotherapy. J Clin Psychiatry 68 (Suppl 10):8-10. (Pubitemid 47507831)
41. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am J Psychiatry 163:1905-1917. (Pubitemid 44807782)
42. Seemuller F, Moller HJ, Obermeier M, Adli M, Bauer M, Kronmuller K, et al. (2010). Do efficacy and effectiveness samples differ in antidepressant treatment outcome? An analysis of eligibility criteria in randomized controlled trials. J Clin Psychiatry 71:1425-1433.
43. Soares CN, Kornstein SG, Thase ME, Jiang Q, Guico-Pabia CJ (2009). Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: A pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials. J Clin Psychiatry 70:1365-1371.
44. Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D (2010). Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord 121:106-115.
45. Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, et al. (2006). Efficacy of quetiapine monotherapy in bipolar I and II depression: A double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 26:600-609. (Pubitemid 44772737)
46. Thase ME, Corya SA, Osuntokun O, Case M, Henley DB, Sanger TM, et al. (2007). A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry 68:224-236. (Pubitemid 46362643)
47. Weisler R, Joyce M, McGill L, Lazarus A, Szamosi J, Eriksson H (2009). Extended release quetiapine fumarate monotherapy for major depressive disorder: Results of a double-blind, randomized, placebo-controlled study. CNS Spectr 14:299-313.
48. Wise TN, Meyers AL, Desaiah D, Mallinckrodt CH, Robinson MJ, Kajdasz DK (2008). The significance of treating somatic symptoms on functional outcome improvement in patients with major depressive disorder: A post hoc analysis of 2 trials. Prim Care Companion J Clin Psychiatry 10:270-275.
49. Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B, et al. (2010). A double-blind, placebo-controlled study of quetiapine and lithium mono-therapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 71:150-162.